¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Drug development research."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
¿µ¹® drug resistance ÇÑ±Û ¾à¹°³»¼º
¼³¸í   
  1. È­Çпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ È­Çпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼­ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈ­µÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ Àִ ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ Àִ ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇϸ頳»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼­ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇϴ °Í µîÀÌ ±× ¿¹ÀÌ´Ù.
¿µ¹® drug dependence ÇÑ±Û ¾à¹°ÀÇÁ¸(¼º)
¼³¸í   
  ¾î¶² Á¾·ùÀÇ ¾à¹°À» ¹Ýº¹Çؼ­ »ç¿ëÇϴ µ¿¾È ±× ¾àÀÇ »ç¿ëÀ» ÁßÁöÇÒ ¼ö ¾ø°Ô µÇ´Â »óÅÂ. ÀÇÁ¸ÀÇ Á¤µµ°¡ ½ÉÇØÁö¸é ¾à ¾øÀ̴ »ýȰÇÒ ¼ö ¾ø´Â »óÅ¿¡ ºüÁö°í, ±× °á°ú ¹ýÀ» ¾î±â¸é¼­±îÁö ¾àÀ» ±¸ÀÔÇϰԠµÈ´Ù. ÀÌÀü¿¡´Â ¾à¹°¸¸¼ºÁßµ¶, ¾à¹°³²¿ë, ¾à¹°½À°ü¼ºÀ̶ó´Â °³³äÀ¸·Î ³ª´©¾îÁ® ÀÖ¾úÁö¸¸, WHO¿¡¼­´Â À̰͵éÀ» ¸ðµÎ Æ÷ÇÔ½ÃÄѼ­ ¾à¹°ÀÇÁ¸À̶ó ÇÏ¿´´Ù.
  
  »óÅ¿¡ ÀÇÇÑ ºÐ·ù¶ó ¾à¹°ÀÛ¿ë¿¡ ÀÇÇÑ ºÐ·ù°¡ ÀÖ´Ù. »óÅ¿¡ ÀÇÇÑ °ÍÀº 
  
  1.Á¤½ÅÀû ÀÇÁ¸: ¾à¹°ÀÇ »ç¿ëÀ» ÁßÁöÇϸ頺ҾȰ¨-¿ì¿ï°¨-ÃÊÁ¶°¨ µîÀÇ ½É¸®ÀûÀΠÁõ»óÀÌ ³ªÅ¸³ª ´Ù½Ã ¾à¹°À» Ã£°Ô µÇ´Â °æ¿ì. ¾àÀ» ²÷¾úÀ» °æ¿ì¿¡ ³ªÅ¸³ª´Â ½ÅüÁõ»óÀΠ±Ý´ÜÁõ»óÀº ³ªÅ¸³ªÁö ¾ÊÀ¸¸ç, ¾à¹°ÀÇ Áö¼ÓÀû º¹¿ë¿¡ ÀÇÇØ¼­ Á¡Â÷ ¾à¹°¿¡ ´ëÇÑ ½ÅüÀÇ ¹ÝÀÀÀÌ ÁÙ¾îµå´Â Çö»óÀΠ¾à¹°ÀÇ ³»¼ºµµ ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  
  2.½ÅüÀû ÀÇÁ¸: ¾à¹° »ç¿ëÀ» ÁßÁöÇϸ頽ÅüÀûÀΠÀå¾Ö, ÁݴÜÁõ»óÀ» ÀÏÀ¸Å°°í ±× °íÅëÀ» ´Þ·¡±â À§ÇØ ¾à¹°À» Ã£°Ô µÇ´Â °æ¿ìÀÌ´Ù. ´ëºÎºÐ ³»¼ºÀÌ ³ªÅ¸³ª´Âµ¥ °³º°ÀûÀ¸·Î ³ªÅ¸³ª´Â °æ¿ìµµ ÀÖÁö¸¸ ÁַΠº´ÇàÇØ¼­ ³ªÅ¸³­´Ù.
¿µ¹® antianginal drug ÇÑ±Û Ç×Çù½ÉÁõÁ¦
¼³¸í   
  Çù½ÉÁõÀº ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°ÔÇϰųª ½ÉÀåÀÌ Ç÷·ù¿¡ ºñÇØ¼­ ¸¹Àº ÀÏÀ» Çϴ °ÍÀ» ¾ïÁ¦ÇÔÀ¸·Î½á Ä¡·áµÉ ¼ö ÀÖ´Ù. ¨ç nitrate°èÅëÀÇ ¾à¹°: Ç÷°üÀ» À̿ϽÃ۴ ÀÛ¿ëÀ» ÇÔÀ¸·Î½á ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù. ¨è Ä®½·Åë·ÎÂ÷´ÜÁ¦(verapamil, nifedipine): ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â CaÀÌ °ü¿©ÇÑ´Ù. Áï CaÀÌ ÀÖ¾î¾ß¸¸ ±ÙÀ°ÀÇ ¼öÃàÀÌ °¡´ÉÇØÁø´Ù. ±×·¯¹Ç·Î CaÀÌ ¼¼Æ÷¼ÓÀ¸·Î µé¾î°¡´Â °ÍÀ» ¾ïÁ¦Çϴ ¾àÁ¦´Â ±ÙÀ°ÀÇ ¼öÃàÀ» ¸·´Â´Ù. ÀÌ ¾àÀº ½ÉÀåÀÇ ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ½ÉÀå ±ÙÀ°ÀÇ ¼öÃàÀ» ¾ïÁ¦Çϸ砽ÉÀåÀÌ °úµµÇϰԠÀÏÇϴ °ÍÀ» ¸·°í, ¶Ç ½ÉÀ嵿¸ÆÀÇ ¼öÃà¿¡ °ü¿©Çϴ ±ÙÀ°¿¡ ÀÛ¿ëÀ» ÇÏ¿© ½ÉÀ嵿¸ÆÀ» À̿ϽÃÄѼ­ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù.
  
  ¨é º£Å¸Â÷´ÜÁ¦(beta-blocker): ½ÅüÀÇ ¿îµ¿·®À̳ª ±âŸÀÇ ¿ä±¸¿¡ ÀÇÇØ¼­ ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇϴ ½Å°æÀº ¹Ù·Î º£Å¸-±³°¨½Å°æÀÌ´Ù. ±³°¨½Å°æ°è¶õ »ç¶÷ÀÌ À§±ÞÇÑ »óȲ¿¡¼­ ÀÛ¿ëÇϴ ÀÚÀ²½Å°æ°èÀÌ´Ù. Áï »ç¶÷ÀÌ ±äÀåÇϰųª ½Î¿ï °æ¿ì¿¡ ÀüÇüÀûÀ¸·Î ±³°¨½Å°æ°è°¡ ÀÛ¿ëÇÑ´Ù. Áï ½ÉÀåÀÌ ¶Ù°Å³ª ¼ÒÈ­°¡ ¾ÊµÇ°Å³ª µ¿°øÀÌ Ä¿Áö´Â °Í µûÀ§°¡ ¹Ù·Î ±³°¨½Å°æ°èÀÇ ¿ªÇÒÀ̶ó°í ÇÒ ¼ö ÀÖ´Ù. ÀÌ ±³°¨½Å°æ°è¿¡¼­ ¸»ÃÊÀå±â¿¡ º¸³»´Â ½Å°æÀÌ ±³°¨½Å°æÀÌ´Ù. ±×·¯¹Ç·Î ½ÉÀå¿¡¼­ ½ÉÀåÀ» ½Åü¿¡ Çʿ信 µû¶ó¼­ ¸¹Àº ÀÏÀ» ÇϰÔÇϴ ½Å°æÀ» Â÷´ÜÇÒ °æ¿ì¿¡´Â Çù½ÉÁõÀ» Ä¡·áÇÒ ¼ö ÀÖ°Ô µÈ´Ù(½ÉÀåÀÇ »ê¼Ò³ª ±âŸ ¿µ¾çºÐÀÇ ¼ö¿ä¸¦ ÁÙÀδÙ).
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • sexual development
    ¼º±â´É¹ß´Þ
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antianxiety drug
    Ç׺ҾÈÁ¦, ºÒ¾ÈÄ¡·áÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticancer drug
    Ç×¾ÏÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antidiabetic drug
    ´ç´¢º´¾à
  • antiemetic drug
    ±¸Åä¾à, Ç×±¸ÅäÁ¦
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹ÎÁ¦
  • antihypertensive drug
    °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
  • antimalarial drug
    ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦
  • antiobestic drug
    »ì»©´Â¾à, ºñ¸¸Ä¡·áÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • psychoactive drug
    Á¤½ÅÀÛ¿ë¾à
  • tranquilizing drug
    Á¤½Å¾ÈÁ¤Á¦, Á¤¿ÂÁ¦
  • tuberculostatic drug
    Ç×°áÇÙÁ¦
  • therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ°¨½Ã
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • drug treatment
    ¾à¹°Ä¡·á
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • emotional development
    °¨Á¤¹ß´Þ
  • heterogonic development
    °£Á¢¹ßÀ°
  • homogonic development
    Á÷Á¢¹ßÀ°
  • mental development
    Áö´É¹ß´Þ
  • moral development
    µµ´ö¹ß´Þ
  • motor development
    ¿îµ¿¹ß´Þ
  • personality development
    ÀΰݹߴÞ
  • psychosexual development
    Á¤½Å¼º¹ß´Þ, Á¤½Å¼º±â´É¹ß´Þ
  • psychosocial development
    Á¤½Å»çȸ¹ß´Þ
  • sensory development
    °¨°¢¹ß´Þ
  • sexual development
    ¼º¹ß´Þ, ¼º±â´É¹ß´Þ
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • NDA : new drug application
    ½Å¾àÇã°¡½Åû.
  • TDM : therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ ¸ð´ÏÅ͸µ.
  • addiction, drug
    ¸¶¾à»ó½À(ئå·ßÈã§)
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°ÈïºÐ¾à, ¾Æµå·¹³¯¸°ÀÚ±ØÁ¦.
  • adulterated drug
    ¼¯À½Áú¾àǰ.[¿¹¹æ]ºÎÁ¤¾àǰ(ËÓËøËâ̰).
  • allergy, drug
    ¾à¹°¾Ë·¹¸£±â
  • antiallergic agent =a. drug
    Ç׾˷¹¸£±â¾à.
  • antiallergic drug
    Ç׾˷¹¸£±â¾à.
  • antiamebic drug
    Ç׾Ƹ޹پà.
  • antianxiety drug
    Ç׺ҾȾà(ù÷ÝÕäÌå·).
  • antiarrhythmic agent =a. drug
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦.
  • anticancer drug
    Ç×¾ÏÁ¦.
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´(Ä¡·á)¾à.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • development history
    ¹ßÀ°¿ª(»ç).
  • development quotient =DQ
    ¹ß´ÞÁö¼ö.
  • development quotient =DQ
    ¹ß´ÞÁö¼ö.
  • ego development
    ÀھƹߴÞ
  • embryonic development
    ¹è¹ß»ý(ÛÏÛ¡ßæ).
  • emotional development
    °¨Á¤Àû ¹ß´Þ
  • face development
  • leukemia development
    ¹éÇ÷º´¹ßº´
  • lymphocyte development
    ¸²ÇÁ±¸¹ßÀ°
  • membranous bone development
    ¸·»À¹ß»ý
  • mental development
    Áö´É¹ßÀ°(ò±ÒöÛ¡ëÀ).
  • moral development
  • personality development
    ÀÎ°Ý ¹ß´Þ
  • postnatal development
    »ýÈĹßÀ°(¡­Û¡ëÀ).
  • prenatal development
    Ãâ»ýÀü¹ßÀ°(¡­Û¡ëÀ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ERDA Energy Research and Development Administration
HSR&D health services research and development
NMRDC Naval Medical Research and Development Command
OSRD Office of Scientific Research and Development
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
D.Q. Development Quotient
HUD Housing and Urban Development
ICDS Integrated Child Development Service
MCD Malformations of Cortical Development
MGDF Megakaryocyte Growth and Development Factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • personality development
    ¼º°Ý ¹ß´Þ
  • psychosexual development
    Á¤½Å¼º ¹ß´Þ
  • sensory development
    °¨°¢ ¹ß´Þ, Áö°¢ ¹ß´Þ
  • addicting drug
    ½À°ü¼º ¾à
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • anesthetic drug
    ¸¶Ãë ¾à
  • antagonistic drug
    ±æÇ× ¾à, ±æÇ×Á¦
  • antiamebic drug
    Ç׾Ƹ޹٠¾à
    ¾Æ¸Þ¹Ù¸¦ »ì¸ê ¶Ç´Â ¹ßÀ°À» ¾ïÁ¦ÇÏ´Â ¾à¹°.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • anticancer drug
    Ç×¾ÏÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
    Ç÷¾×ÀÇ ÀÀ°í¸¦ ¸·´Â ¾àÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´ Ä¡·á ¾à
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
nursing administration research research concerned with establishing costs of nursing care, examining the relationships between nursing services and quality patient care, and viewing problems of nursing service delivery within the broader context of policy analysis and delivery of health services
(12 Dec 1998)
nursing education research Investigations into the problems of integrating research findings into nursing curricula, developing problem solving skills, finding approaches to clinical teaching, determining the level of practice by graduates from different basic preparations, etc.
(12 Dec 1998)
nursing evaluation research Research carried out by nurses that uses interviews, data collection, observation, surveys, etc., to evaluate nursing, health, clinical, and nursing education programs and curricula, and which also demonstrates the value of such evaluation.
(12 Dec 1998)
nursing methodology research Research carried out by nurses concerning techniques and methods to implement projects and to document information, including methods of interviewing patients, collecting data, and forming inferences. The concept includes exploration of methodological issues such as human subjectivity and human experience.
(12 Dec 1998)
nursing research Research carried out by nurses, generally in clinical settings, in the areas of clinical practice, evaluation, nursing education, nursing administration, and methodology.
(12 Dec 1998)
dental research The study of laws, theories, and hypotheses through a systematic examination of pertinent facts and their interpretation in the field of dentistry.
(12 Dec 1998)
operations research A group of techniques developed to apply scientific methods and tools to solve the problems of decision making in complex organizations and systems. Operations research searches for optimal solutions in situations of conflicting goals and makes use of mathematical models from which solutions for actual problems may be derived.
(12 Dec 1998)
epidemiologic research design The form and structure of analytic studies in epidemiologic and clinical research.
(12 Dec 1998)
united states agency for health care policy and research An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research.
(12 Dec 1998)
united states office of research integrity An office of the united states public health service organised in june 1992 to promote research integrity and investigate misconduct in research supported by the public health service. It consolidates the office of scientific integrity of the national institutes of health and the office of scientific integrity review in the office of the assistant secretary for health. The ori is in the office of the assistant secretary for health and its director reports directly to the assistant secretary for health, department of health and human services. (ri newsletter, 1993 jan; 1(1):1)
(12 Dec 1998)
Bayley Scales of Infant Development A psychological test used to measure the developmental progress of infants over the first two and one-half years of life; consists of three scales: mental, motor, and behaviour record.
(05 Mar 2000)
bone development Gross development of bones from foetus to adult. It includes osteogenesis, which is restricted to formation and development of bone from the undifferentiated cells of the germ layers of the embryo. It does not include osseointegration.
(12 Dec 1998)
maxillofacial development The process of growth and differentiation of the jaws and face.
(12 Dec 1998)
child development The continuous sequential physiological and psychological maturing of the child from birth up to but not including adolescence. It includes healthy responses to situations, but does not include growth in stature or size (= growth).
(12 Dec 1998)
child development disorders, pervasive Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • research
    ¿¬±¸
  • Food and Drug Administration
    ½Äǰ ÀǾ౹(º¸°Ç ±³À° º¹Áö¼ºÀÇ ÀϺÎ)
  • combination drug
    º¹ÇÕ¾à(2Á¾ ÀÌ»óÀÇ Ç×»ý ¹°Áú µîÀÇ È¥ÇÕ¾à)
  • counter drug
    ÀÇ»çÀÇ Ã³¹æ ¾øÀÌ ÆÇ¸ÅµÇ´Â ¾à
  • drug
    ¾à;¾àÁ¦;¾àǰ;¸¶¾à;~¿¡ ¾àÀ»³Ö´Ù;¸¶Ãë½ÃŰ´Ù;¹°¸®°ÔÇÏ´Ù
  • drug addict
    ¸¶¾à Áßµ¶ÀÚ
  • drug buster
    (¹Ì)¸¶¾à ´Ü¼Ó°ü 
  • drug design
    (¾à)¾àÁ¦ ¼³°è(À¯È¿¼ºÀ» ³ôÀ̱â À§ÇÑ Á¾ÇÕÀû °³¹ß °ËÅä
  • drug interaction
    (¾à)¾à¹° »óÈ£ ÀÛ¿ë
  • drug pump
    (ÀÇ)¾à ÆßÇÁ(Ç÷°ü ÁÖ»ç¿ë)
  • fertillity drug
    ÀӽŠÃËÁøÁ¦
  • garbage drug
    ¿ªÈ¿°ú¸¦ ÃÊ·¡Çϱ⠽¬¿î ¸¶¾à(Á¢ÂøÁ¦³ª ½Ã³Ê µî)
  • hard drug
    ½À°ü¼º ¸¶¾à
  • listener research
    Àαâ ÇÁ·ÎÁ¶»ç
  • market research
    (Á¦Ç°À» ¸ÅÃâÇϱâ ÀüÀÇ) ½ÃÀå Á¶»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á